Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BION-301
- Development stage
- Preclinical
- Lead developer
- Biond Biologics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antibody-Based Therapeutics
01
Overview
BION-301 is an investigational anti-panKRAS biologic drug developed by Biond Biologics. It utilizes a proprietary antibody cell-internalization technology to target oncogenic KRAS proteins, which are key regulators of cell signaling in many cancers. The drug acts as both a KRAS protein inhibitor and an immunomodulator, aiming to disrupt cancer cell growth and survival by inhibiting mutant KRAS-driven pathways and modulating the immune response against tumor cells. As of the latest updates, BION-301 is classified as a new molecular entity and is in preclinical development for cancer indications[1][2].
- Other names
- BION 301BION301BION-301
02
Targets
Beyond the preview
Go deeper on BION-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BION-301.